The presence of anti-IFN increased the risk of severe disease (OR=7.75; CI=1.79-33.61; P=0.01) and mechanical ventilation in patients with COVID-19 (OR=4.19; CI=2.06-8.53; P<0.001), but not mortality (OR=1.68; CI=0.63-4.44; P=0.3; I2=51.8) (Figure 2). This evidence concerns the gene IFNA1 and COVID-19.